Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced the appointment of Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025. The leadership change positions the biopharmaceutical company to execute its growth strategy as it advances its pipeline of recombinant therapeutic proteins produced through its proprietary plant cell-based expression system.
Leadership Transition and Strategic Vision
Mamlok will succeed Eyal Rubin, who has served as CFO for the past six years. To ensure continuity, Mamlok has already joined the company and is working alongside Rubin during the transition period. Rubin will remain available to the company through October 2025.
"With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix team," said Dror Bashan, Protalix's President and Chief Executive Officer.
Bashan acknowledged Rubin's contributions, stating that he "contributed significantly to Protalix's transformation, strengthening the Company's capital and financial status and preparing the Company for growth."
Executive Background and Expertise
Mamlok brings extensive experience in capital markets transactions, mergers and acquisitions, business development, and investor relations. Most recently, he served as Chief Financial Officer of TytoCare Ltd., a privately-held remote healthcare company. Prior to TytoCare, he held the CFO position at Sol-Gel Technologies Ltd., where he managed an initial public offering and various capital markets transactions, along with in-licensing and out-licensing deals.
His healthcare industry experience includes roles at medical device companies, notably Given Imaging, which was acquired by Covidien plc in 2014. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics from Tel Aviv University.
Proprietary Technology Platform
Protalix operates through its proprietary ProCellEx plant cell-based protein expression system, making it the first company to gain FDA approval for a protein produced through plant cell-based suspension expression technology. This platform represents a novel industrial-scale method for developing recombinant proteins.
The company has established significant partnerships for its approved products. Pfizer Inc. holds worldwide development and commercialization rights to taliglucerase alfa for Gaucher disease treatment, excluding Brazil where Protalix retains full rights. The company's second product, Elfabrio, received approval from both the FDA and European Medicines Agency in May 2023, with global development and commercialization managed through a partnership with Chiesi Farmaceutici S.p.A.
Development Pipeline
Protalix's pipeline includes proprietary recombinant therapeutic proteins targeting established pharmaceutical markets. Key candidates include PRX-115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout treatment, and PRX-119, a plant cell-expressed long-action DNase I for NETs-related diseases treatment.
